Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-10-11

Clinical Trial Update: Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia has been terminated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bendamustine (Bendamustine)
  • Idelalisib (idelalisib)
  • Rituximab (rituximab)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: TERMINATED | Results posted: 2017-10-11